Therapy: Are TNF inhibitors safe in pregnancy?

Nature Reviews Rheumatology

Volumn 5, Issue 4, 2009, Pages 184-185

  Østensen, Monika ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; CONGENITAL MALFORMATION; DRUG ANTAGONISM; FEMALE; HUMAN; NOTE; PREGNANCY;

ABNORMALITIES, DRUG-INDUCED; ANIMALS; FEMALE; HUMANS; PREGNANCY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67650446412     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2009.47     Document Type: Article

References (10)

1. Hyrich, K., Symmons, D., Watson, K. & Silman, A. Pregnancy outcome in women who were exposed to anti-TNF agents: results from a national population register. Arthritis Rheum. 54, 2701-2702 (2006).
2. Berthelot, J. M. et al. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 76, 28-34 (2009).
3. Carter, J. D. et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the FDA database. J. Rheumatol. doi:10.3899/jrheum.080545 (2008).
4. Carter, J., Valeriano, J. & Vasey, F. B. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship? J. Rheumatol. 33, 1014-1017 (2006).
5. Kallen, K., Mastroiacovo, P, Castilla, E. E., Robert, E. & Kallen, B. VATER non-random association of congenital malformations: study based on data from four malformation registers. Am. J. Med. Gen. 101, 26-32 (2001).
6. Katz, J. A. et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am. J. Gastroenterol. 99, 2385-2392 (2004).
7. Winger, E. E. & Reed, J. L. Treatment with tumor necrosis factor inhibitors and intravenous immunoglobulin improves live birth rates in women with recurrent spontaneous abortion. Am. J. Reprod. Immunol. 60, 8-16 (2008).
8. Chambers, C. D., Tutuncu, Z. N., Johnson, D. & Jones, K. L. Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data. Arthritis Res. Ther. 8, 215 (2006).
9. Johnson, D. L., Jones, K. L. & Chambers, C. D. Pregnancy outcome in women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy project. Ann. Rheum. Dis. 66 (Suppl. 2), 174 (2007).
10. Ostensen, M. et al. Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum. Ann. Rheum. Dis. 64, 839-844 (2005).